» Articles » PMID: 35905416

Frailty As Tested by the Clinical Frailty Scale Is a Risk Factor for Hepatorenal Syndrome in Patients With Liver Cirrhosis

Abstract

Introduction: Frailty is common in patients with cirrhosis and increases the vulnerability to internal and external stressors. This study aimed to investigate the impact of frailty, as defined by the Clinical Frailty Scale (CFS), on the risk of acute kidney injury (AKI) and hepatorenal syndrome (HRS-AKI) in hospitalized patients with liver cirrhosis.

Methods: We analyzed data of 201 nonelectively hospitalized patients with cirrhosis and without higher-grade chronic kidney disease. Patient characteristics were captured within the first 24 hours of hospital admission, and frailty was assessed using the CFS. Patients were followed for the development of AKI and/or HRS-AKI during the hospital stay.

Results: In the total cohort, median CFS was 3 (interquartile range 3-4), and 34 (16.9%) patients were frail (CFS >4). During the hospital stay, 110 (54.7%) and 49 (24.3%) patients developed AKI or HRS-AKI, respectively. Patients with AKI or HRS-AKI had a significantly higher CFS than patients without kidney injury (P < 0.001 each). In multivariable analyses, a higher CFS was independently associated with the development of AKI (odds ratio [OR] 1.467, 95% confidence interval (CI) 1.065-2.021) in the total cohort and HRS-AKI (OR 1.809, 95% CI 1.263-2.591) in the subcohort of patients with a history of ascites. In addition, there was a strong association between frailty (OR 3.717, 95% CI 1.456-9.491) and HRS-AKI.

Discussion: Frailty in patients with cirrhosis is associated with AKI and HRS-AKI. In this context, CFS appears to be a reliable tool to identify patients at high risk for developing AKI or HRS-AKI on hospital admission.

Citing Articles

New Scanographic Index for the Detection of Frailty in Patients with Cirrhosis with a Prognostic Impact.

El Khoueiry C, Slim R, Rida M, Khoury B, Honein K, Smayra T Middle East J Dig Dis. 2024; 16(2):102-108.

PMID: 39131107 PMC: 11316193. DOI: 10.34172/mejdd.2024.376.


Frailty in end-stage liver disease: Understanding pathophysiology, tools for assessment, and strategies for management.

Elsheikh M, El Sabagh A, Mohamed I, Bhongade M, Hassan M, Jalal P World J Gastroenterol. 2023; 29(46):6028-6048.

PMID: 38130738 PMC: 10731159. DOI: 10.3748/wjg.v29.i46.6028.


Pathophysiology and management of liver cirrhosis: from portal hypertension to acute-on-chronic liver failure.

Jagdish R, Roy A, Kumar K, Premkumar M, Sharma M, Rao P Front Med (Lausanne). 2023; 10:1060073.

PMID: 37396918 PMC: 10311004. DOI: 10.3389/fmed.2023.1060073.


Improving the prognosis before and after liver transplantation: Is muscle a game changer?.

Goffaux A, Delorme A, Dahlqvist G, Lanthier N World J Gastroenterol. 2022; 28(40):5807-5817.

PMID: 36353207 PMC: 9639652. DOI: 10.3748/wjg.v28.i40.5807.

References
1.
Jiesisibieke Z, Tung T, Xu Q, Chen P, Hsu S, Liu Y . Association of acute kidney injury with frailty in elderly population: a systematic review and meta-analysis. Ren Fail. 2019; 41(1):1021-1027. PMC: 6913666. DOI: 10.1080/0886022X.2019.1679644. View

2.
Bassegoda O, Huelin P, Ariza X, Sole C, Juanola A, Gratacos-Gines J . Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes. J Hepatol. 2020; 72(6):1132-1139. DOI: 10.1016/j.jhep.2019.12.020. View

3.
Rockwood K, Song X, MacKnight C, Bergman H, Hogan D, McDowell I . A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005; 173(5):489-95. PMC: 1188185. DOI: 10.1503/cmaj.050051. View

4.
Sunaga A, Hikoso S, Yamada T, Yasumura Y, Uematsu M, Tamaki S . Prognostic impact of Clinical Frailty Scale in patients with heart failure with preserved ejection fraction. ESC Heart Fail. 2021; 8(4):3316-3326. PMC: 8318468. DOI: 10.1002/ehf2.13482. View

5.
Qu T, Yang H, Walston J, Fedarko N, Leng S . Upregulated monocytic expression of CXC chemokine ligand 10 (CXCL-10) and its relationship with serum interleukin-6 levels in the syndrome of frailty. Cytokine. 2009; 46(3):319-24. PMC: 3159181. DOI: 10.1016/j.cyto.2009.02.015. View